Narciclasine modulates the Rho/ROCK/LIM kinase/cofilin pathway; stimulates RhoA activation and induces actin polymerization. The cytostatic activity of Narciclasine involves the impairment of actin cytoskeleton organization by targeting GTPases, including RhoA and the elongation factor eEF1A. Thus, Narciclasine is a potentially promising agent for the treatment of primary brain cancers and various brain metastases. Also Narciclasine is an actin stress fiber formation inducer; a plant growth modulator.